Lyell Immunopharma, Inc. Contract Liability (Deferred Revenue)
Lyell Immunopharma, Inc. (LYEL) had Contract Liability (Deferred Revenue) of $0 as of 2022-12-31, per its 10-K filed 2023-02-28.
Discontinued › Balance Sheet › Liabilities
us-gaap:ContractWithCustomerLiabilityCurrent · last filed 2023-02-28
- 2022-12-31: Contract with Customer, Liability, Current $0.00.
- 2022-09-30: Contract with Customer, Liability, Current $11.19M.
- 2022-06-30: Contract with Customer, Liability, Current $15.43M.
- 2022-03-31: Contract with Customer, Liability, Current $6.22M.
| Period end | Contract with Customer, Liability, Current |
|---|---|
| 2022-12-31 | $0.00 10-K · filed 2023-02-28 |
| 2022-09-30 | $11.19M 10-Q · filed 2022-11-08 |
| 2022-06-30 | $15.43M 10-Q · filed 2022-08-04 |
| 2022-03-31 | $6.22M 10-Q · filed 2022-05-10 |
| 2021-12-31 | $4.99M 10-K · filed 2023-02-28 |
| 2021-09-30 | $5.58M 10-Q · filed 2021-11-12 |
| 2021-06-30 | $8.23M 10-Q · filed 2021-08-12 |
| 2020-12-31 | $6.09M 10-K · filed 2022-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |